STATUS OF DISEASE BY NOVEL CORONAVIRUS AND ANALYSIS OF MORTALITY IN MÉXICO, UNTIL JULY 31, 2020
NICOLÁS PADILLA- RAYGOZA *
School of Medicine, University of Celaya, Celaya, Mexico.
CUAUHTÉMOC-SANDOVAL- SALAZAR
Department of Nursing and Obstetrics, Division of Health Sciences and Engineering, Campus Celaya-Salvatierra, University of Guanajuato, Celaya, Mexico.
XÓCHITL SOFÍA RAMÍREZ- GÓMEZ
Department of Clinical Nursing, Division of Health Sciences and Engineering, Campus Celaya-Salvatierra, University of Guanajuato, Celaya, Mexico.
LUIS ANTONIO DÍAZ- BECERRIL
School of Medicine, University of Celaya, Celaya, Mexico.
EFRAÍN NAVARRO- OLIVOS
Institute of Public Health from Guanajuato, State, Guanajuato, Mexico.
MARÍA DE JESÚS GALLARDO- LUNA
Institute of Public Health from Guanajuato, State, Guanajuato, Mexico.
FRANCISCO J. MAGOS VÁZQUEZ
Institute of Public Health from Guanajuato, State, Guanajuato, Mexico.
DANIEL ALBERTO DÍAZ- MARTÍNEZ
Institute of Public Health from Guanajuato, State, Guanajuato, Mexico.
*Author to whom correspondence should be addressed.
Abstract
Background: With the emergence of a SARS-CoV-2 infection pandemic in China and its spread to other countries, mortality was shown to be high and to a greater extent if there were underlying pathologies.
Methods: It is an ecological analytical (cases for Mexican states) and cross-sectional study (individual data), of the open records of confirmed and discarded cases for COVID-19 of the General Directorate of Epidemiology of the Ministry of Health of Mexico.
Results: A specific mortality of 10.99% is reported; being higher in men between with age 65 or higher. Mortality rates from underlying diseases were higher than those reported in the World Health Organization in United States of America and Brazil in August 2020. Asthma was found to be a protective factor for COVID-19 mortality.
Conclusion: It is concluded that mortality was higher in the presence of comorbidities.
Keywords: SARS-CoV-2, COVID-19, mortality, co-morbidities.